miklos pless
机构: Kantonsspital Winterthur
每年引用次数
引用次数
引用: 15,662
H-指数: 48
I10-指数 : 106
出版物: 371
P-606 Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss group for clinical cancer research (SAKK)
Roger Stupp , Rolf A. Stahel , Roger Kann , Daniel Betticher
Lung Cancer 41
2003
P-592 Neoadjuvant chemo- and radiotherapy in stage IIIA (N2) non-small cell lung cancer (NSCLC). Rationale for a radomized trial by the swiss group for clinical cancer research (SAKK)
Miklos Pless , Rolf Stahel , Sabine Balmer-Majno , Roger Stupp
Lung Cancer 41
2003
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Sacha I. Rothschild , Daniel Betticher , Reinhard Zenhäusern , Sandro Anchisi
Cancer Chemotherapy and Pharmacology 84 ( 4) 881 -889
2
2019
A phase II clinical trial of tumor-treating field (TTF) therapy concomitant to pemetrexed for advanced non-small cell lung cancer (NSCLC).
Miklos Pless , Daniel C. Betticher , Cornelia M. Droege , Marc Oliver Salzberg
Journal of Clinical Oncology 30 ( 15_suppl) e18012 -e18012
1
2012
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Richard Cathomas , Julian Schardt , Miklos Pless , Anna Llado
Swiss Medical Weekly 150 ( 1920)
2020
Tumor treating fields: concept, evidence and future.
Miklos Pless , Uri Weinberg
Expert Opinion on Investigational Drugs 20 ( 8) 1099 -1106
95
2011
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Christoph Mamot , Dirk Klingbiel , Felicitas Hitz , Christoph Renner
Journal of Clinical Oncology 33 ( 23) 2523 -2529
98
2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.
Julien Mazières , Fabrice Barlesi , Thomas Filleron , Benjamin Besse
Journal of Clinical Oncology 33 11076 -11076
2015
Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).
J. Randolph Hecht , Miklos Pless , Antonio Cubillo , Aitana Calvo
Journal of Clinical Oncology 38 3015 -3015
2
2020
Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Sophie Reinhart , Yasmin Trachsel , Christine Fritz , Ulrich Wagner
Urology 146 32 -35
7
2020
Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
Jacques Cadranel , Keunchil Park , Oscar Arrieta , Miklos Pless
Lung Cancer 98 9 -14
20
2016
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Miguel-Angel Molina-Vila , Rolf A. Stahel , Urania Dafni , Núria Jordana-Ariza
Journal of Thoracic Oncology 15 ( 3) 416 -425
8
2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Solange Peters , Sarah Danson , Baktiar Hasan , Urania Dafni
Journal of Thoracic Oncology 15 ( 10) 1647 -1656
5
2020
Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08)
Martin Früh , Richard Cathomas , Marco Siano , Gregor Tscherry
Clinical Lung Cancer 14 ( 1) 34 -39
18
2013
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi , Nicholas Mach , Sacha I Rothschild , Qiyu Li
Clinical Lung Cancer 16 ( 5) 358 -365
12
2015
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Oliver Gautschi , Sacha I Rothschild , Qiyu Li , Klazien Matter-Walstra
Clinical Lung Cancer 18 ( 3) 303 -309
6
2017
Are Four Simple Questions Able to Predict Weight Loss in Outpatients With Metastatic Cancer? A Prospective Cohort Study Assessing the Simplified Nutritional Appetite Questionnaire
Seth F. Helfenstein , Alexandra Uster , Maya Rühlin , Miklos Pless
Nutrition and Cancer 68 ( 5) 743 -749
4
2016
PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09)
Sacha Rothschild , Oliver Gautschi , Nathalie Schuster , Qiyu Li
Journal of Thoracic Oncology 12 ( 1) S1471
2017
P2.03a-004 Second-line Therapy Improves Overall Survival in Primary Refractory Non Small-Cell Lung Cancer (NSCLC) Patients: Topic: Clinical Trials
Sacha Rothschild , Rebecca Nachbur , Jakob Passweg , Miklos Pless
Journal of Thoracic Oncology 12 ( 1)
2017
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Miklos Pless , Roger Stupp , Hans-Beat Ris , Rolf A Stahel
The Lancet 386 ( 9998) 1049 -1056
169
2015